Boston Scientific Settles With SEC On 1997/98 Japan Sales Irregularities
This article was originally published in The Gray Sheet
Executive Summary
A settlement reached between Boston Scientific and the Securities and Exchange Commission in connection with improperly recorded sales by the company's Japanese operation does not include a fine.
You may also be interested in...
Boston Scientific Expects PMA Supplement To Further Delay SOX Re-Launch
Boston Scientific likely will submit data to FDA in the form of a premarket approval application supplement for the relaunch of the Nir-On-Ranger with SOX securement system, leading analysts to envisage a second-half 1999 return to market for the pre-mounted coronary stent system.
Boston Scientific To Report Q3 Results By Nov. 14 Despite Japan Difficulties
The detection of $40-50 mil. in improperly recorded sales in 1998 by Boston Scientific's Japan subsidiary is bittersweet testimony to the effectiveness of the firm's recently installed corporate SAP computer system.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.